A decade after Congress permitted federal money for clean needle programs, the Trump administration’s withdrawal of support now jeopardizes progress against hepatitis C, a potentially fatal but treatable virus. Experts warn that reversing support for these programs could undermine the strides made in reducing transmission rates.